AIM
TVTX icon

Acrospire Investment Management’s Travere Therapeutics TVTX Stock Holding History

Acrospire Investment Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,400
Closed -$44K – 2542
2017
Q1 		$44K Sell
2,400
-5,200
-68% -$102K 0.04% 1066
2016
Q4 		$144K Buy
7,600
+3,900
+105% +$79.8K 0.06% 651
2016
Q3 		$83K Sell
3,700
-1,000
-21% -$19K 0.06% 691
2016
Q2 		$84K Buy
4,700
+2,000
+74% +$32.4K 0.06% 617
2016
Q1 		$37K Buy
+2,700
New +$41K 0.03% 1184

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acrospire Investment Management's TVTX Position: Q2 2017 in Review

Acrospire Investment Management sold out of Travere Therapeutics (TVTX) in Q2 2017, closing a stake of 2,400 shares — an estimated $44K sold.

Acrospire Investment Management first reported a position in TVTX in Q1 2016 and held it in 5 quarters. The position peaked at $144K in Q4 2016. 108 funds tracked by Wall St. Rank hold TVTX as of Q2 2017.

  • Acrospire Investment Management reported no remaining Travere Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 2,400 Travere Therapeutics shares in Q2 2017, an estimated $44K.
  • Acrospire Investment Management first reported a position in Travere Therapeutics in Q1 2016 and held it in 5 quarters.
  • Acrospire Investment Management's Travere Therapeutics position peaked at $144K in Q4 2016.
  • 108 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.